(Q36987442)

17 August 2017

1 reference

title

Therapeutic leukocytapheresis for inflammatory bowel disease (English)

1 reference

inflammatory bowel diseases

17 August 2017

main subject

0 references

inflammation

0 references

author name string

Abbi R Saniabadi

1

1 reference

17 August 2017

Hiroyuki Hanai

2

1 reference

17 August 2017

Ken Fukunaga

3

1 reference

17 August 2017

Koji Sawada

4

1 reference

17 August 2017

Chikako Shima

5

1 reference

17 August 2017

Ingvar Bjarnason

6

1 reference

17 August 2017

Robert Lofberg

7

1 reference

17 August 2017

publication date

31 October 2007

1 reference

Transfusion and Apheresis Science

17 August 2017

published in

1 reference

17 August 2017

volume

37

1 reference

17 August 2017

issue

2

1 reference

17 August 2017

page(s)

191-200

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRANSCI.2007.08.003

17 August 2017

1 reference

Dietary antigens as aggravating factors in Crohn's disease

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRANSCI.2007.08.003

Sulfasalazine. Adverse effects and desensitization

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRANSCI.2007.08.003

Medical therapy for ulcerative colitis 2004.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRANSCI.2007.08.003

Intensive intravenous regimen for severe attacks of ulcerative colitis.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRANSCI.2007.08.003

Nutrition and Gastrointestinal Disease

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRANSCI.2007.08.003

Treatment of Crohn's disease with anti-tumor necrosis factor chimeric monoclonal antibody (cA2).

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRANSCI.2007.08.003

Can cyclosporine go it alone in severe ulcerative colitis?

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRANSCI.2007.08.003

Review article: a critical approach to new forms of treatment of Crohn's disease and ulcerative colitis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRANSCI.2007.08.003

Tumor necrosis factor antagonist therapy and lymphoma development: twenty-six cases reported to the Food and Drug Administration

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRANSCI.2007.08.003

Adacolumn, an adsorptive carrier based granulocyte and monocyte apheresis device for the treatment of inflammatory and refractory diseases associated with leukocytes

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRANSCI.2007.08.003

Selective granulocyte and monocyte adsorptive apheresis as a first-line treatment for steroid naïve patients with active ulcerative colitis: a prospective uncontrolled study

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRANSCI.2007.08.003

Adacolumn selective leukocyte adsorption apheresis in patients with active ulcerative colitis: clinical efficacy, effects on plasma IL-8, and expression of Toll-like receptor 2 on granulocytes

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRANSCI.2007.08.003

Peripheral blood neutrophils in inflammatory bowel disease: morphological evidence of in vivo activation in active disease

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRANSCI.2007.08.003

Neutrophil apoptosis is delayed in patients with inflammatory bowel disease

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRANSCI.2007.08.003

Inhibition of apoptosis and prolongation of neutrophil functional longevity by inflammatory mediators.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRANSCI.2007.08.003

Surrogate markers of intestinal inflammation are predictive of relapse in patients with inflammatory bowel disease

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRANSCI.2007.08.003

Tumour necrosis factor α and interleukin 1β in relapse of Crohn's disease

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRANSCI.2007.08.003

Role of cytokines in the pathogenesis of inflammatory bowel disease

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRANSCI.2007.08.003

The production of cytokines by polymorphonuclear neutrophils

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRANSCI.2007.08.003

Increased secretion of pro-inflammatory cytokines by circulating polymorphonuclear neutrophils and regulation by interleukin 10 during intestinal inflammation

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRANSCI.2007.08.003

IL-23: a master regulator in Crohn disease

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRANSCI.2007.08.003

Human neutrophil Fc receptor-mediated adhesion under flow: a hollow fibre model of intravascular arrest.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRANSCI.2007.08.003

Studies on the mechanisms of leukocyte adhesion to cellulose acetate beads: an in vitro model to assess the efficacy of cellulose acetate carrier-based granulocyte and monocyte adsorptive apheresis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRANSCI.2007.08.003

Adacolumn for selective leukocytapheresis as a non-pharmacological treatment for patients with disorders of the immune system: an adjunct or an alternative to drug therapy?

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRANSCI.2007.08.003

Positions of selective leukocytapheresis in the medical therapy of ulcerative colitis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRANSCI.2007.08.003

Treating ulcerative colitis without medications--"look mom, no drugs!"

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRANSCI.2007.08.003

Therapeutic efficacy of granulocyte and monocyte adsorption apheresis in severe active ulcerative colitis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRANSCI.2007.08.003

Leukocyte adsorptive apheresis for the treatment of active ulcerative colitis: a prospective, uncontrolled, pilot study

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRANSCI.2007.08.003

Clinical evaluation of granulocyte/monocyte apheresis therapy for active ulcerative colitis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRANSCI.2007.08.003

Impact of selective leukocytapheresis on mucosal inflammation and ulcerative colitis: cytokine profiles and endoscopic findings

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRANSCI.2007.08.003

Open label trial of granulocyte apheresis suggests therapeutic efficacy in chronically active steroid refractory ulcerative colitis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRANSCI.2007.08.003

A retrospective search for predictors of clinical response to selective granulocyte and monocyte apheresis in patients with ulcerative colitis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRANSCI.2007.08.003

Granulocyteaphaeresis in steroid-dependent inflammatory bowel disease: a prospective, open, pilot study.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRANSCI.2007.08.003

Down-regulation of interferon-gamma parallels clinical response to selective leukocyte apheresis in patients with inflammatory bowel disease: a 12-month follow-up study.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRANSCI.2007.08.003

Adsorptive granulocyte and monocyte apheresis for refractory Crohn's disease: an open multicenter prospective study

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRANSCI.2007.08.003

Adhesion dependent release of hepatocyte growth factor and interleukin-1 receptor antagonist from human blood granulocytes and monocytes: evidence for the involvement of plasma IgG, complement C3 and beta2 integrin

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRANSCI.2007.08.003

The logics of leukocytapheresis as a natural biological therapy for inflammatory bowel disease

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRANSCI.2007.08.003

Correlation of serum soluble TNF-alpha receptors I and II levels with disease activity in patients with ulcerative colitis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRANSCI.2007.08.003

Effects of adacolumn selective leukocytapheresis on plasma cytokines during active disease in patients with active ulcerative colitis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRANSCI.2007.08.003

Blocking IL-1: interleukin 1 receptor antagonist in vivo and in vitro

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRANSCI.2007.08.003

Hepatocyte growth factor facilitates colonic mucosal repair in experimental ulcerative colitis in rats

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRANSCI.2007.08.003

The proinflammatory CD14+CD16+DR++ monocytes are a major source of TNF.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRANSCI.2007.08.003

Proinflammatory blood monocytes: main effector and target cells in systemic and renal disease; background and therapeutic implications.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRANSCI.2007.08.003

Clinical application of human CD4+ CD25+ regulatory T cells for the treatment of inflammatory bowel diseases

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRANSCI.2007.08.003

Peripheral and intestinal regulatory CD4+ CD25(high) T cells in inflammatory bowel disease.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRANSCI.2007.08.003

CD4+CD25+ Regulatory T Cells Cure Murine Colitis: The Role of IL-10, TGF-β, and CTLA4

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRANSCI.2007.08.003

Cutting Edge: TGF- Signaling Is Required for the In Vivo Expansion and Immunosuppressive Capacity of Regulatory CD4+CD25+ T Cells

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRANSCI.2007.08.003

A role for TGF-beta in the generation and expansion of CD4+CD25+ regulatory T cells from human peripheral blood

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRANSCI.2007.08.003

T cells that cannot respond to TGF-beta escape control by CD4(+)CD25(+) regulatory T cells

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRANSCI.2007.08.003

Regulatory T cells and intestinal homeostasis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRANSCI.2007.08.003

Demonstration of low-regulatory CD25High+CD4+ and high-pro-inflammatory CD28-CD4+ T-Cell subsets in patients with ulcerative colitis: modified by selective granulocyte and monocyte adsorption apheresis.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRANSCI.2007.08.003

Treatment of Crohn's disease by lymphocyte apheresis: a randomized controlled trial. Groupe d'Etudes Thérapeutiques des Affections Inflammatoires Digestives

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRANSCI.2007.08.003

10.1016/J.TRANSCI.2007.08.003

7 January 2021

Identifiers

DOI

1 reference

17 August 2017

1 reference